3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Neoplasms
8
Lung Neoplasms
6
Neoplasms by Site
3
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
alectinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts